Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Anal Toxicol ; 25(7): 576-82, 2001 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11599603

RESUMEN

The most common chemicals that can be ingested and lead to greater than endogenous levels of gamma-hydroxybutyric acid (GHB) in decedents are salts of GHB, gamma-butyrolactone (GBL), and 1,4-butanediol (BD). Results for three deaths involving the ingestion of one or another of these three chemicals, which led to findings of GHB in the decedents, are presented. An extraction procedure that facilitates the quantitation of GHB was developed. If present in the same specimen, both GHB and GBL can be quantitated. To determine the GBL concentration, the specimen is first analyzed for existing GHB, the GBL is then converted to GHB, and the analysis is repeated. The difference between the results in molarity units can yield the GBL concentration. A separate procedure was utilized for estimating concentrations of BD. Specimens analyzed included urine, blood, ocular fluid, brain, and solutions consumed by the decedents prior to death. The procedures were found to be convenient in as much as they are relatively rapid, precise, and economical.


Asunto(s)
4-Butirolactona/envenenamiento , Butileno Glicoles/envenenamiento , Hidroxibutiratos/análisis , Hidroxibutiratos/envenenamiento , Solventes/envenenamiento , Autopsia , Técnicas de Química Analítica/métodos , Humanos , Intoxicación/diagnóstico , Distribución Tisular
2.
Cancer Res ; 58(9): 1876-85, 1998 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-9581828

RESUMEN

Beta-lapachone (beta-lap) affects a number of enzymes in vitro, including type I topoisomerase (Topo I); however, its exact intracellular target(s) and mechanism of cell killing remain unknown. We compared the cytotoxic responses of MCF-7:WS8 (MCF-7) human breast cancer cells after 4-h pulses of beta-lap or camptothecin (CPT), a known Topo I poison. A direct correlation between loss of survival and apoptosis was seen after beta-lap treatment (LD50 = 2.5 microM). A concentration-dependent, transient sub-2 N preapoptotic cell population was observed at 4-8 h. Estrogen deprivation-induced synchronization and bromodeoxyuridine-labeling studies revealed an apoptotic exit point near the G1-S border. Apoptosis activated by beta-lap was closely correlated with cleavage of lamin B but not with increases in p53/p21 or decreases in bcl-2. Loss of hyperphosphorylated forms of the retinoblastoma protein was observed within 5 h, but cyclins A, B1, and E levels were unaltered for up to 72 h after 5 microM beta-lap. Topo I and Topo IIalpha levels decreased at > 24 h. Logarithmic-phase MCF-7 cells were not affected by < or = 1 microM beta-lap. In contrast, dramatic and irreversible G2-M arrest with no apoptosis was observed in MCF-7 cells treated with 1 microM CPT, monitored for 6-10 days posttreatment. MCF-7 cells treated with supralethal doses of CPT (5 microM) resulted in only approximately 20% apoptosis. No correlation between apoptosis and loss of survival was observed. MCF-7 cells exposed to > 5 microM CPT arrested at key cell cycle checkpoints (i.e., G1, S, and G2-M), with little or no movement for 6 days. Ten-fold increases in p53/p21 and 2-5-fold decreases in bcl-2, Topo I, Topo IIalpha, and cyclins A and B1, with no change in cyclin E, were observed. Temporal decreases in bcl-2 and cleavage of lamin B corresponded to the minimal apoptotic response observed. Beta-lap activated apoptosis without inducing p53/p21 or cell cycle arrest responses and killed MCF-7 cells solely by apoptosis. In contrast, concentration-dependent increases in nuclear p53/p21 and various cell cycle checkpoint arrests were seen in MCF-7 cells after CPT. Despite dramatic p53/p21 protein induction responses, CPT-treated MCF-7 cells showed low levels of apoptosis, possibly due to protective cell cycle checkpoints or the lack of specific CPT-activated apoptotic pathways in MCF-7 cells.


Asunto(s)
Apoptosis/efectos de los fármacos , Neoplasias de la Mama/patología , Naftoquinonas/farmacología , Inhibidores de la Transcriptasa Inversa/farmacología , Antineoplásicos Fitogénicos/farmacología , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/metabolismo , Camptotecina/farmacología , Ciclo Celular/efectos de los fármacos , Proteínas de Ciclo Celular/metabolismo , Supervivencia Celular/efectos de los fármacos , Inhibidor p21 de las Quinasas Dependientes de la Ciclina , Ciclinas/metabolismo , ADN-Topoisomerasas de Tipo I/metabolismo , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Dosificación Letal Mediana , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Células Tumorales Cultivadas/efectos de los fármacos , Células Tumorales Cultivadas/metabolismo , Proteína p53 Supresora de Tumor/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...